Marc-Antoni Racing has licensed a collection of patented energy storage technologies developed at ORNL. The technologies focus on components that enable fast-charging, energy-dense batteries for electric and hybrid vehicles and grid storage.
Researchers at ORNL explored radium’s chemistry to advance cancer treatments using ionizing radiation.
Researchers at the Department of Energy’s Oak Ridge National Laboratory and their technologies have received seven 2022 R&D 100 Awards, plus special recognition for a battery-related green technology product.
ORNL Corporate Fellow and Center for Nanophase Materials Sciences researcher Bobby Sumpter has been named fellow of two scientific professional societies: the Institute of Physics and the International Association of Advanced Materials.
To solve a long-standing puzzle about how long a neutron can “live” outside an atomic nucleus, physicists entertained a wild but testable theory positing the existence of a right-handed version of our left-handed universe.
Two decades in the making, a new flagship facility for nuclear physics opened on May 2, and scientists from the Department of Energy’s Oak Ridge National Laboratory have a hand in 10 of its first 34 experiments.
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
University of Pennsylvania researchers called on computational systems biology expertise at Oak Ridge National Laboratory to analyze large datasets of single-cell RNA sequencing from skin samples afflicted with atopic dermatitis.
ORNL, TVA and TNECD were recognized by the Federal Laboratory Consortium for their impactful partnership that resulted in a record $2.3 billion investment by Ultium Cells, a General Motors and LG Energy Solution joint venture, to build a battery cell manufacturing plant in Spring Hill, Tennessee.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.